A. Z. Bluming
University of Southern California, Encino, CA 685.
Background: To assess the incidence of contralateral or recurrent breast cancer among women prospectively treated with HRT after initial breast cancer diagnosis.
Methods: A community-based prospective, single-arm, pilot study of HRT among 232 women with previously treated primary breast cancer.
Results: Median duration of HRT is 73+ months (range 121 36+). Median interval from initial surgery to initiation of HRT is 57 months (range 2-36 1 months). Follow-up to date is 100%. Actual disease-free survival (DFS), disease-specific survival (DSS), & median duration of HRT by stage are:
Seventy four patients have stopped HRT (32%), 37 because of breast cancer development ( 1 6%), 2 because of the development of non-breast cancers, 2 died of nonmalignant disease, 2 because of HRT-associated symptoms, 1 because of pulmonary emboli without clinical phlebitis, and 30 because of anxiety about taking HRT. Actuarial DFS to 20 years for T 1N0 patients was 73% versus 56% for comparable T 1N0 patients who did not receive HRT. Conclusions: No evidence to date of increased development, recurrence or of breast cancer-related death associated with post diagnosis HRT.
No significant financial relationships to disclose.
References
Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement), 2004: 685 © 2004 American Society of Clinical Oncology.